TrialNature medicine2025

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Gerhardt Attard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.